Well, that was fun yesterday - not!
The easy thing to do is to go outside and remove myself from the screen
But, heck I'm not going to do that - these are valuable lessons that need to be learnt - the hard way!
Days like yesterday certainty separated the wheat from the chaff.
The FDA process to get a BLA for approval is complex, long and costly.
We are getting to the pointy end of this process with ODAC review, if you want to get the facts then do yourself a favour and read this
https://hotcopper.com.au/posts/46449348/singleMy sentiments has not changed:
- There is no way that the FDA has set up Mesoblast to fail
- There is no way that the FDA would have issues with Mesoblast and didn't inform Mesoblast throughout this process
- There is no way that the FDA would allow for even more patients to be treated by the same product and mechanism of production for Covid-19 ARDS and MIS-C; where is their duty of care to these patients?
- There is no way that the FDA would ask for an RCT now, if they needed an RCT - wouldn't they have informed Mesoblast that was the only pathway to approval?
- This is not a charade, it is serious life-saving medical & scientific process
- ...
The only conclusion that I have is that this is all an exit strategy for the professional Sharts.
Yes, they are good - damn good and have been able to wait for the right opportunity to compound the fear
This will show up with a reduced % of shorts on MSB - I have no doubts
So, where to today?
My guess is that we will start on a back foot and the SP will be continued to be driven down
But, at some point during the day we'll start our climb upwards
There will be enough institutions that can see value here
Investing require a lot of conviction and a dash of courage
Now that same courage is required for the conviction to HODL
BTW - I'll be interested to hear from anyone who actually invested in a company that went through the FDA approval and Adcomm - that would be a great post to read
(20min delay)